About CBR

Since the company’s founding, Cord Blood Registry® (CBR®) has led the industry in technical innovations
and provided families with access to current
treatments and experimental stem cell therapies for
conditions that have no cure.

Weng family
Banked 2012, 2014

Company Overview

Cord Blood Registry (CBR) is the world’s largest newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing samples from more than 500,000 children. CBR is dedicated to advancing the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure today.

CBR has helped more than 300 families use their cord blood stem cells for established and experimental medical treatments, more than any other family cord blood bank. CBR’s goal is to expand the potential scope of newborn stem cell therapies that may be available to patients and their families.

Cord Blood Registry is headquartered in San Bruno, California. CBR’s owned 80,000 square foot laboratory is located in Tucson, Arizona.

Cord Blood Registry is a registered trademark of CBR Systems, Inc.

History of Quality

CBR maintains standards for cellular therapy services through AABB accreditation, FDA-registration, and CLIA certification.

CBR has the longest history of accreditation with the AABB (formerly known as the American Association of Blood Banks) and the company’s quality standards have been recognized through ISO 9001:2008 certification — the global business standard for quality.

Advancing Medicine

A pioneer in newborn stem cell collection and cryopreservation, CBR believes in the power of newborn stem cells to improve lives today and their potential to revolutionize treatment for many conditions in the future.

CBR is the first family newborn stem cell bank to partner with leading research institutions to establish FDA-regulated clinical trials exploring the potential regenerative ability of stem cells to help treat conditions that have no cure today, including: acquired hearing loss, autism, cerebral palsy, and pediatric stroke. In fact, 73% of the stem cell units released by CBR have been used for experimental regenerative therapies – more than any other family cord blood bank in the world.


CBR created the world’s only collection device designed specifically for cord blood stem cells. CBR’s CellAdvantage® Collection Kit contains everything the healthcare provider needs to help maximize the cord blood collection volume.

CBR developed a crush-resistant, temperature protected, and electronically tracked kit that actively transforms into a cube to encase the blood and/or tissue collection, helping to ensure that it is protected and delivered safely. On average, the transport time from the hospital to CBR’s lab is 19 hours. CBR processes cord blood using the AutoXpress® Platform* (AXP®) — a fully automated, functionally closed stem cell processing technology. CBR has the industry’s highest published average cell recovery rate of 99%.1-3,8

*AXP and AutoXpress are registered trademarks of ThermoGenesis Corp

CBR Executive Team

A team is only as strong as its leadership. Our commitment to helping families starts at the top with our executives.

Geoffrey Crouse
Geoffrey Crouse
Chief Executive Officer

Geoffrey Crouse joined CBR as CEO in September 2012. He previously served as Chief Operating Officer at Immucor, a publicly traded global in vitro diagnostics company that was sold to TPG in 2011. Prior to Immucor, he served as vice president of the life sciences business at Millipore Corporation, a NYSE-traded provider of technologies, tools and services for the global life science industry. In this role, he led the Life Science Strategic Business Unit, a global laboratory consumables and reagents business. Prior to joining Millipore, he worked at Roche, a leader in the pharmaceuticals and diagnostics industries, where he led market development and government affairs for the diagnostics division based in Basel, Switzerland. Geoffrey earned a B.A. from Boston College and an M.B.A. and Masters of Public Health from the University of California at Berkeley.

Heather Brown
Heather Brown
Vice President, Scientific and Medical Affairs

Heather Brown has been with CBR since 2001 and has more than 20 years of clinical and business experience in the healthcare and biotech industries. Heather is a board certified genetic counselor with extensive experience in prenatal, pediatric, and cancer genetics. She has led a number of new business development and healthcare marketing initiatives during her tenure at CBR. In her current role, she is primarily responsible for research partnerships, clinical trial management, and medical need-based programs. Heather holds a B.A. and M.S. in Health and Medical Sciences from the University of California at Berkeley.

Mike Johnson
Mike Johnson
Chief Financial Officer

Mike Johnson joined CBR as CFO in January 2013. Mike was most recently the CFO of Fenwal, a global blood technology company dedicated to supporting transfusion medicine and cell therapies. He successfully managed a carve-out of the Fenwal business from Baxter in 2006. From 2006 to 2012 he led the global finance and IT organizations through a business transformation that supported international integration of a stand-alone business and resulted in significant value creation. TPG, a large private equity firm, recently sold the business to Fresenius. Prior to Fenwal, he spent almost 10 years in senior financial roles at Dade Behring, a leading medical diagnostics company, including Corporate Controller, and V.P. Finance for the manufacturing, supply chain and R&D organizations. Mike has a B.S. in Accounting from the University of Illinois and an M.B.A. from the University of Chicago.

Todd Van Horn
Todd Van Horn
Vice President, Business Development

Todd Van Horn oversees all business development activities including strategic partnerships, mergers and acquisitions, and collaborations. Additionally, Todd is responsible for CBR’s business intelligence team supporting and guiding CBR’s commercial strategy and tactics. Prior to joining CBR, he was a Principal at Linden Capital Partners, a healthcare and life sciences-focused private equity firm. While at Linden, he sourced new investments, led diligence activities, structured deals, worked closely with senior management teams, and led various strategic and M&A initiatives at portfolio companies. He served on the board of Directors for CORPAK MedSystems and StrataDx, and was a board observer at Behavioral Centers of America. Prior to Linden, he was a Principal and founding member of Healthcare Investment Partners, a growth equity healthcare fund, and began his career in the healthcare investment banking group at Credit Suisse First Boston where he provided M&A advisory services and executed financing transactions for healthcare and life science companies. Todd holds a B.S. in Molecular, Cell and Developmental Biology from the University of California, Los Angeles and an M.B.A. from the Kellogg School of Management with majors in Health Industry Management and Finance.

Sign up for free information and special offers. Ready to enroll? Start here, too.